The United Kingdom and the United States have announced a landmark bilateral deal that will preserve no levies on British drug products entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to boost spending on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these crucial products will stay at nothing for a timeframe of the next three years.
This deal is in response to earlier statements to dramatically increase tariffs on patented drug imports, with potential rates floated up to one hundred percent.
"This agreement with the Britain reinforces the international landscape for new treatments and establishes much-needed equity to transatlantic medicine commerce," an announcement noted.
Economic Importance
Medicines represent one of the Britain's biggest export categories to the US, which is clearly the biggest buyer for major British pharmaceutical firms.
Statistics indicate that in the one-year period leading up to last September, the UK sold medicines valued at £11.1bn to the US. This value accounted for nearly one-fifth of British export trade in that period.
"This agreement safeguards work, stimulates funding and facilitates the UK to emerge as a international leader for life sciences," a minister remarked.
Detailed NHS Changes
The agreement involves several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to raise total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount drug companies must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Last year, refunds topped twenty percent.
Broader Context
The deal follows a ongoing tension between the sector and the ministers over medicine costs and regulatory access.
The disagreement were exacerbated by assertions that US customers were charged a premium for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister acknowledged that the NHS had to spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the last ten years.
